Summit: Ivonescimab beats pembrolizumab in Phase III HARMONi-2 for PD-L1+ NSCLC

Summit Therapeutics Inc.

Ivonescimab met primary endpoint PFS with statistically significant and clinically meaningful superiority over pembrolizumab.
Benefit observed across subgroups: PD-L1 low/high, squamous/non-squamous, and high-risk patients.
First drug to show statistically significant superiority over pembrolizumab in a head-to-head Phase III NSCLC trial.
Full data set to be presented at upcoming major medical conference; conference call June 3 at 8am ET.
Summit plans to expand development of ivonescimab into other tumors beyond NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.